CDMO Kindeva Drug Delivery has received a grant from the UK government’s Life Sciences Innovation Manufacturing Fund (LSIMF), unlocking a £33 million investment with Kindeva toward enhancing inhaler manufacturing and sustainability.
The joint funds enhance Kindeva’s capability and capacity to manufacture the next generation of green pressurised metered-dose inhalers (pMDIs) and to continue delivering ever-evolving therapies for respiratory diseases worldwide.
David Stevens, Kindeva Global CCO, said: “This joint investment of public and private funds creates myriad new opportunities for Kindeva colleagues within the UK as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation products.”
Stevens continued: “This investment provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with leading pharmaceutical companies around the world to bring the next generation of green inhalers to market — with a common goal of safeguarding access to necessary therapies for patients and reducing our impact on the planet.”
This investment provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with leading pharmaceutical companies around the world
- David Stevens, Kindeva Global CCO
This investment supports global development and manufacturing of inhalers using new, lower global warming potential (GWP) propellants, while creating and safeguarding local jobs across the company’s two UK sites — Loughborough and Clitheroe. Additionally, this industry and government investment supports:
- New manufacturing capability and capacity in Loughborough for the next generation of green inhalers
- Green improvements to Kindeva’s underlying inhaler componentry supply chain at the company’s Clitheroe site
- Pharmaceutical companies as they make green transitions with existing products —reducing GWP emissions and helping meet sustainability targets — as well as the opportunity to bring new green inhalers and respiratory therapies to patients
The UK grant is the sixth investment through the LSIMF, which has supported UK life sciences manufacturing with £340 million in joint government and industry backing in the last financial year.
Minister of State for Science, Research & Innovation, George Freeman MP, said: “Our £94 billion life science sector is one of our great industries - based on a deep long-term partnership between industry, investors, government, the NHS and disease charities - supporting us all to live healthier lives and providing over 250,000 high-skilled jobs in research and development clusters all around the UK.”
